Results 41 to 50 of about 12,125 (226)

Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window

Clinics, 2021
OBJECTIVES: To investigate the safety and efficacy of combined tirofiban-ozagrel therapy for treating progressive stroke patients out of thrombolytic therapy time window.
Huiying Zhang, Lei Zheng
doaj   +1 more source

Impact of Tirofiban on Serum Troponin Changes in Patients Undergoing Carotid Artery Stenting: A Propensity Matched Analysis

, 2020
Background: The optional periprocedural antithrombotic management for carotid artery stenting (CAS) is still debated.Methods: We aimed to compare the procedural and 1-month outlook of patients undergoing CAS with tirofiban as parenteral antiplatelet ...
Carulli, Eugenio, Biondi-Zoccai, Giuseppe, Ferraro, Paolo, Conte, Sirio, Corcione, Nicola, Cavarretta, Elena, Avellino, Raffaella, Giordano, Arturo, Morello, Alberto, Pepe, Martino   +9 more
core   +2 more sources

Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.

JAMA Neurology
Importance Evidence supports using antiplatelet therapy in patients with acute ischemic stroke. However, neurological deterioration remains common under the currently recommended antiplatelet regimen, leading to poor clinical outcomes.
Wen-Bo Zhao, Si-Jia Li, Chuan-Hui Li, Chuan-Jie Wu, Jun-Mei Wang, Li-Fei Xing, Yue Wan, Jin-Hui Qin, Yao-Ming Xu, Rui-Xian Wang, Chang-Ming Wen, Ai-Ming Wang, Lan Liu, Jing Wang, Hai-Qing Song, Wu-Wei Feng, Qing-Feng Ma, Xun-Ming Ji, Jian-Ping Ding, Ping-Ping Wang, Yuan Wang, Xiao-Jun Hao, Bu-Rong Bian, Guan-Qing Feng, Yu-Jia Xie, Hui Wen, Xin Yang, Wen-Zhao Li, Yue-Jiang Gui, Jing Hao, Ya-Qiong Zhang, Qing Zhao, Yang Yang, Ru-Tao Liu, Shan-Chao Zhang, Zhi-Hui Si, Shan Qiao, Shan Xu, Jing Yuan, Ya-Juan Shao, Fang-Kai Dai, Guo-Feng Zhang, Yan-Chao Huo, Wen-Jing Zhou, Lu Yang, Xu-Fei Cheng, Ming Wang, Hai-Dong Hou, Hai-Yin Wang, Hong-Liang Yan, Ya-Juan Fu, Bo-Wen Zang, Mei-Ping Zhao, Ping-Ping Wen, Jian-Ying Lv, Xiao-Jing Lian, Mei-Juan Kang, Zai-Hang Zhang, Qing Zhang, Zai-Yu Guo, Lian-Hua Zhao, Xiao-Liang Liu, Jing Zheng, Shang-Sheng Ke, Ling-Huang Shao, X. Liu, X. Tao, Ying-Bing Ke, H. Liu, Dan-Dan He   +69 more
semanticscholar   +1 more source

Efficacy and safety of tirofiban in acute ischemic stroke patients with ideal reperfusion: A cohort study of LAA and CE subgroups

European Journal of Neurology
Despite achieving ideal reperfusion (eTICI = 3) through endovascular treatment (EVT), some acute ischemic stroke (AIS) patients still experience poor outcomes.
C. Yue, Xiang Liu, Chang-Yu Guo, Li-Lan Wang, Wenlong Zhao, Wen-Zhe Sun, Jia-Xing Song, Jie Yang, Lin-Yu Li, N. Yu, Shi-Hai Yang, Xiao-Lei Shi, Jia-Cheng Huang, W. Kong, Zhen-Qiang Li, Shun-Yu Yang, Shuang Yang, W. Zi, Yi Lin, Feng-Li Li   +19 more
semanticscholar   +1 more source

Cerebral No‐Reflow after Thrombectomy: International Delphi Consensus on Definition and Imaging Assessment

Annals of Neurology, EarlyView.
Background The operational definition and imaging assessment of the no‐reflow phenomenon, a potential contributor to poor clinical outcome despite successful thrombectomy, remains debated. We aimed to develop expert‐based international consensus on the definition, assessment, and reporting standard of cerebral no‐reflow post‐thrombectomy. Methods Three‐
Adnan Mujanovic, Samantha Rivet, Adrien ter Schiphorst, Jean‐Claude Baron, Johannes Kaesmacher, Felix Ng, Cerebral No‐Reflow Delphi‐Consensus Group, Pooja Khatri, Xin Cheng, Andrea Zini, Maria Hernandez Perez, Ettore Nicolini, Marta Rubiera, Charlotte Rosso, Marie Luby, Victor Del Brutto, Christopher Favilla, Angel Chamorro, Angelika Hoffman, David Liebeskind, Sven P. R. Luijten, Moritz Hernandez Petzsche   +21 more
wiley   +1 more source

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant

Journal of Interventional Medicine, 2020
Objective: To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.
Qiao Deng, Shichao Zhang, Mingzhou Li, Guozhong Zhang, Wenfeng Feng   +4 more
doaj   +1 more source

Intravenous tirofiban in acute ischemic stroke patients not receiving reperfusion treatments: a systematic review and meta-analysis of randomized controlled trials

Frontiers in Neurology
Background Reperfusion treatments with intravenous thrombolysis and endovascular thrombectomy after acute ischemic stroke (AIS) can improve patients’ outcomes significantly.
Shatha Alqurashi, M. Alqahtani, S. Albeladi, Saleha Almahdawi, Hala E Danish, Hatoon Alshaikh, Ahmed Alkhiri, Ammar AlKawi, F. Al-Ajlan, A. Alhazzani   +9 more
semanticscholar   +1 more source

Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High‐Risk Percutaneous Coronary Interventions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP).
Siyu Ma, Wendy Y. Cheng, Yinong Liang, Josephine Bryar, Gwyneth Wei, Joshua D. Niznik, Christina Yin, Sue Liu‐Yi, Jimmy L. Kerrigan   +8 more
wiley   +1 more source

Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: A post hoc analysis of the TREND Trial

European Stroke Journal
Introduction: The degree of culprit artery stenosis affects the risk of early neurological deterioration (END) after acute ischemic stroke (AIS). The TREND trial demonstrated the efficacy of tirofiban in preventing END in patients with AIS.
Jing Wang, Yue Qiao, Si-Jia Li, Chuan-Hui Li, Chuan-Jie Wu, Ping-Ping Wang, Ting Yang, Xun-Ming Ji, Qing-Feng Ma, Wen-Bo Zhao   +9 more
semanticscholar   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source